ORIGINAL RESEARCH
Accepted on 04 May 2026
Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy
- 126 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Endocrine Immune-Related Toxicities during Treatment of Lung Cancer with Immune Checkpoint Inhibitors
Endocrine Immune-Related Toxicities during Treatment of Lung Cancer with Immune Checkpoint Inhibitors
795
Total downloads
5,141
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 01 Apr 2026
Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis
doi 10.3389/fimmu.2026.1757532
- 474 views
CASE REPORT
Published on 23 Mar 2026
PD-1 inhibitor-induced systemic sclerosis with early interstitial lung disease and autoimmune thyroiditis in advanced gastric cancer: a case report and literature review
doi 10.3389/fonc.2026.1776228
- 396 views
- 1 citation
CASE REPORT
Published on 20 Mar 2026
Case Report: A case of diabetes mellitus and pneumonitis induced by envafolimab treatment in small cell lung cancer
doi 10.3389/fimmu.2026.1708071
- 422 views
- 1 citation
PERSPECTIVE
Published on 10 Feb 2026
Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer
doi 10.3389/fimmu.2026.1741875
- 564 views
CASE REPORT
Published on 19 Jan 2026
Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation
doi 10.3389/fimmu.2025.1747371
- 1,337 views
- 1 citation
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Other participating journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: